Comparative Pharmacology
Head-to-head clinical analysis: EXSERVAN versus MAGNACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXSERVAN versus MAGNACORT.
EXSERVAN vs MAGNACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Exservan (riluzole) is a benzothiazole derivative that modulates glutamatergic neurotransmission. Its mechanism of action involves inhibition of glutamate release, inactivation of voltage-dependent sodium channels, and interference with neurotransmitter binding to excitatory amino acid receptors.
Corticosteroid receptor agonist; modulates gene transcription to produce anti-inflammatory and immunosuppressive effects.
Adults: 15 mg orally once daily in the morning; increase to 30 mg after 2 weeks if needed. Maximum 30 mg/day.
5 mg orally once daily for 7 days, then 5 mg orally every other day for 7 days. Alternatively, 1 mg/kg intravenously every 12 hours for 14 days.
None Documented
None Documented
Terminal elimination half-life is approximately 3–4 hours in patients with normal renal function; prolonged in renal impairment (up to 8–10 hours in ESRD).
3.5 ± 0.8 hours (terminal); prolonged in renal impairment (up to 12 hours in ESRD) and hepatic disease; requires dose adjustment in CrCl <30 mL/min
Primarily renal excretion as unchanged drug: 80% excreted unchanged in urine; approximately 20% as metabolites; biliary/fecal <5%.
Renal (80% as unchanged drug and metabolites, primarily via glomerular filtration and tubular secretion); biliary/fecal (15%)
Category C
Category C
Corticosteroid
Corticosteroid